Make an inquiry
Refer a patient

We noticed you are on our US page. Want to switch regions? Choose from the options:

Make an inquiry
Refer a patient

We noticed you are on our US page. Want to switch regions? Choose from the options:

Find a location
Find a doctor

TG Therapeutics 304

A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic

Trial overview

Topic

TG Therapeutics 304

Description

This study evaluates the combination of ublituximab, a novel monoclonal antibody, and TGR-1202, a novel PI3K delta inhibitor compared to obinutuzumab and chlorambucil, and compared to ublituximab or TGR-1202 alone in Chronic Lymphocytic Leukemia (CLL).

 

Physicians

Contact

North Florida / Jacksonville

Astrid Corrales-Cruz

(904) 427-1217